Clinical Research Directory
Browse clinical research sites, groups, and studies.
Decitabine for Poor Graft Function Post Allo-HSCT
Sponsor: The First Affiliated Hospital of Soochow University
Summary
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
Official title: Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
16 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2023-07-01
Completion Date
2026-11-01
Last Updated
2023-06-18
Healthy Volunteers
No
Conditions
Interventions
Decitabine
Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
Granulocyte Colony-Stimulating Factor
5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
Thrombopoietin Receptor Agonist
Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
Recombinant human erythropoietin
10000 U/day when hemoglobin ≤ 85 g/L